Barclays Maintains Overweight on Elevance Health, Lowers Price Target to $457

Benzinga Newsdesk www.benzinga.com Negative 75.3%

Neg 75.3% Neu 0% Pos 0%

Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $480 to $457.